Aflibercept (VEGF Trap) 

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease^[1][2][3].

Human

Aflibercept (500 μg/mL; 24 小时和 7 天) 对 RPE 细胞无毒性，无论是在 MTT 测定还是在台盼蓝排除测定中均未发现^[1]。
Aflibercept (500 μg/mL; 24 小时) 对具有三个伤口的融合 RPE 细胞层中的伤口愈合具有统计学上显着的影响^[1]。
Aflibercept (500 μg/mL; 7 天) 对调理乳胶珠的吞噬作用显着降低与未经处理的对照组相比^[1]。
Aflibercept (1 和 10 μg/mL; 10 小时) 通过降低 VEGF 调节的过程（例如通透性和血管生成）来抑制 VEGF 信号传导^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Aflibercept（10 mg/kg；大脑中动脉闭塞 (MCAO) 后 3 小时）可降低中风引起的 VEGF-A 和 VEGFR2 表达、脑水肿和 BBB 破坏，并改善肥胖小鼠中风后存活率^[2]。
Aflibercept（18.2 mg/kg 和 36.4 mg/kg；静脉注射一次）可影响小鼠的血压、ROS 和 eNOS 生成^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

862111-32-8

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98(10):1448-52.  [Content Brief]

  [2]. Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648.  [Content Brief]

  [3]. Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42(9):1437-1448.  [Content Brief]